Ulf Grawunder starts new Life Science Company
Ulf Grawunder was co-founder and CTO of 4-Antibody. In 2012 he started a new company called NBE Therapeutics. The new start-up has already secured seed funding.
NBE-Therapeutics is a new Biopharmaceutical venture that has been incorporated in Basel, Switzerland, in April 2012. NBE-Therapeutics will focus its activities on the development, optimization and marketing of technologies and product opportunities for New Biological Entities (NBEs), with the vision to create advanced and powerful therapies for human diseases.
In addition to technology and product development in the area of NBEs, NBE-Therapeutics will offer consulting for Biotechnology, Biopharmaceutical and Pharmaceutical companies that intend to discover, develop, acquire or divest technologies, or product opportunities, in particular related to antibody-based NBEs.
The company will start activities in the second half of 2012, starting with consulting services, before engaging in the development and marketing of new technologies and product opportunities in the area of NBEs.
Founder and first CEO of NBE therapeutics is Ulf Grawunder. He has long standing experience in the field of therapeutic antibody discovery and development and will be able to leverage his technical expertise and his network in the industry for the development of a pipeline of cutting-edge antibody-based therapeutics, including, but not limited to antibody drug conjugates, and bi-specific antibodies. Ulf Grawunder was co-founder and CTO of 4-Antibody, a start-up focused antibody discovery and development.
NBE announced in April 2012 that it had closed a seed funding round. A private investor had invested an undisclosed sum.
Please login or sign up to comment.
Commenting guidelines